FR901228 in Treating Patients With Relapsed or Refractory Advanced Ovarian Epithelial Cancer

Withdrawn before enrolling · Phase 2

Conditions studied: Ovarian Cancer

In brief

RATIONALE: FR901228 may stop the growth of tumor cells by blocking the enzymes necessary for their growth. PURPOSE: This phase II trial is studying how well FR901228 works in treating patients with relapsed or refractory advanced ovarian epithelial cancer.

Key facts

Study ID

NCT00085527

Run by

University of Chicago

People needed

0

Starts

2005-05-01

Expected to finish

2005-09-01

Last updated by the study team

2013-09-05

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

Where it is running

• Cardinal Bernardin Cancer Center at Loyola University Medical Center — Maywood, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.